Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
The disease burden of pyoderma gangrenosum (PG) is poorly understood.
To determine standardized overall and age-, sex-, and race-specific prevalence estimates for PG among adults in the United States.
Cross-sectional analysis of 1971 patients with PG identified using electronic health records data from a diverse population-based sample of more than 58 million patients.
The age- and sex-standardized prevalence of PG among the study population was 0.0058%, or 5.8 PG cases (95% confidence interval [CI], 5.6-6.1) per 100,000 adults. Adjusted prevalence was nearly twice as high among women (7.1 cases [95% CI, 6.7-7.5] per 100,000) than men (4.4 cases [95% CI, 4.0-4.7] per 100,000). Patients between the ages of 70 and 79 years had the highest standardized prevalence (9.8 cases [95% CI, 8.8-10.9] per 100,000), with patients aged ≥50 years representing nearly 70% of all PG cases. Standardized prevalence was similar among white and African American patients. The female-to-male ratio of PG was >1.8 across all age groups.
Analysis of electronic health records data may result in misclassification bias.
PG is a rare disease that most commonly affects women and those aged ≥50 years.Le texte complet de cet article est disponible en PDF.
Key words : epidemiology, female, prevalence, pyoderma gangrenosum
Abbreviations used : CI, IBD, ICD, IL, PG, SNOMED-CT, US
| Funding sources: None
| Conflicts of interest: Dr Garg has served as an advisor for AbbVie, Amgen, Janssen, Pfizer, UCB, and Asana Biosciences, and has received honoraria. Dr Alloo serves as a consultant for Gemstone Biotherapeutics. Authors Xu, Balgobind, and Strunk have no conflicts of interest to report.